| Backgroud: Ulcerative colitis (UC) is a kind of etiology, pathogenesis is still not very clear colon rectum and chronic nonspecific inflammation disease, lesions mainly involving mucosal and the submucosa, clinical manifestation mainly for abdominal pain, diarrhea, mucous bloody stool, and accompanied by some parenteral and systemic expression. Currently most scholars think that promote inflammatory cells factors and anti-inflammatory cytokines unbalance of the pathogenesis of UC plays a very important role, and the role of oxygen free radicals (OFR) injury on UC incidence also has become a hotspot. Etiasa for mesalazine particles, effective ingredients is particles for 5 - amino salicylic acid (5 - ASA) is the main drug treatment of UC.Its action mechanism is to curb the colonic mucosa release leukotriene, scavenging oxidative radicals etc, restrain the activation of damage factor leukocytes produce inflammation neurotransmitter. bifid-triple viable capsule contains the colon bacillus, lactobacillus acidophilus and enterococcus. The unique coating technology can make living bacterium arrive intestinal tract resist gastric acid and completely released. It can raise endogenous defense shield, restrain and remove the intestinal tract pathogen, adjust the intestinal flora balance, reduce enterogenous toxins produce, thus achieve the purpose of the UC treatment.Objective: To explore the effects of combination of Etiasa and bifid-triple viable capsule on serum cytokines such as Tumor Necrosis Factorα(TNF-α), Interleukin 10(IL-10 ), Interleukin 8(IL-8) and oxygen free radicals index such as malondialdehyde, superoxide dismutase in patients with ulcerative colitis (UC).Methods: Thirty-eight patients with UC were randomly divided into two groups:ontrol group(n=19) and treatment group(n=19) . Patients in Control group were given mesalazine therapy, patients in treatment group were added Bifico 420mg, tid on this basis, 2 months as a course. Before and after the treatment, fasting peripheral venous blood were taken for further study .Serum TNF-α, IL-8,IL-10 concentrations were measured by the method of double antibody sandwich enzyme-linked immunosorbent assay, and serum SOD concentration was tested by the method of nitrite, MDA was tested by TBA coloration method . During the whole process of useing drug ,observe patients abdominal pain, diarrhea, tenesmus etc of clinical symptoms change and rating.Results:①In therapy group, the levels of TNF-α,IL-8, were lower than that before treatment respectively,the differences were all significant(P<0.01), the levels of IL-10 were higher than that before treatment respectively,the differences was also significant(P<0.01). There were significant differences in TNF-α,IL-8 and IL-10 before and after treatment between two groups(P<0.01).②After treatment,MDA level in 2 groups were decreased (P <0.05),SOD level were increased(P<0.05); the difference between the two groups before and after treatment was statistically significant (P <0.05).③clinical symptom scores in 2 groups of patients all declined than before treatment (P < 0.05), the difference was statistically significant. But the treatment group, the clinical symptom scores dropped significantly greater than in control group (P < 0.05), the difference was statistically significant. By the clinical curative effect assessment, treatment group total(89.5%) is more effective than control group(78.9%), the difference was statistically significant. (P< 0.05). Conclusions: Compared with single therapy of Etiasa, combination of Etiasa and Bifico canmore effectively inhibits inflammatory reactions, alleviate clinical symptoms, Its mechanism is probably related to reducing patients serum TNF alpha, IL - 8 level, and improving the level of IL– 10; reducing the MDA level, increasing superoxide dismutase vigor, so it can achieve the purpose of UC treatment. |
PDF Full Text Request